The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

SPRY FINANCIAL STATEMENTS

ARS Pharmaceuticals, Inc — balance sheet, income statement and cash flow trends

SPRYARS Pharmaceuticals, Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-200 M-100 M0100 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue116.9 M $Gross Profit86.4 M $ · 74%Operating Income-216.3 M $ · -185%Pre-tax Income-215.5 M $ · -184%Net Income to Owners-215.4 M $ · -184%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue116.9 M $+4.1%
Gross Profit86.4 M $-13.0%
Operating Income-216.3 M $—
EBITDA-209 M $—
Net Income to Owners-215.4 M $—

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0200 M400 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets249.5 M
  • Equity12.5 M $5%
  • Current Liabilities60.9 M $24%
  • Long-term Liabilities176.1 M $71%

Key Figures

YoY change
Total Assets249.5 M $-20.4%
Total Liabilities237 M $+95.6%
Total Equity12.5 M $-93.5%
Cash & ST Investments143.8 M $-40.1%
Total Debt——
Net Debt-8.2 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-200 M-100 M0202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-200 M-100 M0-196.4 M $Operating48.5 M $Investing104.5 M $Financing-43.4 M $Net Change

Key Figures

YoY change
Operating Cash Flow-196.4 M $—
Capital Expenditures197 K $-66.3%
Free Cash Flow-196.6 M $—
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on SPRY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 2, 26. This content is for informational purposes only and is not investment advice.